CUA Educational Content

PSMA PET/CT Beyond the Images: The Imager’s and Clinician’s Perspective

EDITORIAL COMMITTEE: Bobby Shayegan, Katherine Zukotynski, Frédéric Pouliot, Stefano Fanti

By the end of this program, participants will be able to:

  • Describe the several PSMA-targeting tracers and PET/CT technology
  • Describe the accuracy of PSMA-PET/CT for staging and re-staging prostate cancer based on best prospective studies
  • Understand the basis of PSMA radioligand therapy and the trials in metastatic prostate cancer



This program has received financial support from The ICPO Foundation, Oncidium Foundation, and Advanced Accelerator Applications: A Novartis Company in the form of an educational grant